Synergy Disc posts 87.1% success at 24 months without stats to back superiority claim
Synergy Spine Solutions says its cervical disc beat fusion surgery, but the release carries no p-values or confidence intervals behind that claim.
Executive Summary
- Synergy Spine Solutions reported a composite success rate at 24 months from its U.S. investigational device study, framing the number as proof its cervical disc beats standard fusion surgery.
- The disclosure omits the statistical detail, effect size, and confidence interval that would let a clinician or investor judge whether the reported margin over fusion is real or within noise.
- The device already has FDA approval for single-level cervical disc replacement, so this data readout serves as supporting evidence for adoption, not a regulatory decision point.
- The cervical disc replacement landscape holds several devices from established orthopedic sponsors, and this trial's registered completion timeline moved by more than a year and went dark for over two years before results emerged.
The claim
Synergy Spine Solutions said its Synergy Disc achieved an 87.1% composite clinical success rate at 24 months in the trial registered as NCT04469231, and that patients treated with the device reported lower neck and arm pain scores and higher satisfaction than the anterior cervical discectomy and fusion (ACDF) control group. The release states this demonstrates superiority to ACDF, a long-standing surgical treatment for cervical degenerative disc disease. No p-value, confidence interval, or effect size accompanies the claim in the disclosure. SynergySynergy Disc® Reaches 100 U.S. Cases in 100 Days Following FDA Approval, Advancing Motion-Preserving Cervical Disc Replacement in the U.S.Jul 21, 2026
What the trial tested
The study enrolled 175 patients under an open-label, single-arm registry design comparing the Synergy Disc against ACDF in patients with single-level symptomatic cervical degenerative disc disease. The registered primary outcome measure is device-related adverse events, a safety endpoint, rather than the composite clinical success metric the press release leads with. That distinction matters: a composite success rate reported without its component breakdown or statistical test does not by itself establish the primary safety endpoint result. NCT04469231The Synergy Disc To Anterior Cervical Discectomy and FusionNCT04469231
Already on the market
The Synergy Disc already holds FDA Premarket Approval for single-level cervical disc replacement from C3 to C7, granted earlier in 2026, and the company has separately reported the device reaching 100 U.S. commercial cases within 100 days of its first procedure. That approval places this data disclosure in a confirmatory role: it supports an already-cleared device rather than gating a pending regulatory decision. Neurosurgeon Todd Lanman, who participated in the IDE trial and performed the first commercial U.S. procedure, said the device combines motion preservation with alignment restoration to "better replicate the spine's natural biomechanics". SynergySynergy Disc® Reaches 100 U.S. Cases in 100 Days Following FDA Approval, Advancing Motion-Preserving Cervical Disc Replacement in the U.S.Jul 21, 2026
Trial timeline
The trial's primary completion date moved from January 2024 to January 2025, then again to June 2025, a cumulative delay of roughly a year against its original schedule. Enrollment was revised down from an anticipated 190 patients to an actual 175 in mid-2023, when the trial also shifted from recruiting to active, not recruiting. The registry record then went without an update for more than two years before this result surfaced, a pattern consistent with a device that had already moved past its formal trial phase and into commercial launch by the time results were disclosed. NCT04469231The Synergy Disc To Anterior Cervical Discectomy and FusionNCT04469231
The competitive field
Cervical disc replacement is a populated device category: Medtronic's PRESTIGE LP Cervical Disc, ZimVie's Mobi-C Cervical Disc Arthroplasty, NuVasive's Simplify Cervical Artificial Disc, and DePuy International's Discover Cervical Artificial Disc all have registered trials in the same indication. Each competes on the same underlying premise, motion preservation as an alternative to fusion, so the differentiator among them tends to be design detail rather than mechanism. Synergy's device is built with a 6-degree lordotic core intended to restore cervical alignment alongside motion preservation, and uses a nickel-free titanium alloy the company says can broaden access for patients with nickel sensitivities, an allergy affecting up to 17% of women and 3% of men by published estimates. Whether that alignment-restoration design translates into a durable clinical edge over rival discs is a question this disclosure, on its own, does not resolve. SynergySynergy Disc® Reaches 100 U.S. Cases in 100 Days Following FDA Approval, Advancing Motion-Preserving Cervical Disc Replacement in the U.S.Jul 21, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.